Galectin Therapeutics/$GALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Ticker
$GALT
Sector
Primary listing
Employees
15
Headquarters
Website
GALT Metrics
BasicAdvanced
$302M
-
-$0.64
0.83
-
Price and volume
Market cap
$302M
Beta
0.83
52-week high
$6.55
52-week low
$0.73
Average daily volume
323K
Financial strength
Current ratio
1.432
Quick ratio
1.278
Long term debt to equity
-104.121
Total debt to equity
-104.165
Interest coverage (TTM)
-5.01%
Profitability
Management effectiveness
Return on assets (TTM)
-98.30%
Return on equity (TTM)
40.48%
Valuation
Price to book
-2.53
Price to tangible book (TTM)
-2.53
Price to free cash flow (TTM)
-8.338
Free cash flow yield (TTM)
-11.99%
Free cash flow per share (TTM)
-0.566
Growth
Earnings per share change (TTM)
-17.75%
3-year earnings per share growth (CAGR)
2.50%
10-year earnings per share growth (CAGR)
-1.95%
What the Analysts think about GALT
Analyst ratings (Buy, Hold, Sell) for Galectin Therapeutics stock.
Bulls say / Bears say
Positive clinical feedback at the European Association for the Study of the Liver in May 2025 demonstrated that belapectin produced a clinically meaningful response in FibroScan® measurements across various MASH cirrhosis stages, highlighting its therapeutic potential (GlobeNewswire).
The company is reducing single-asset risk and broadening its portfolio by partnering with academic investigators to develop treatments for additional fibrotic and oncologic indications (ATTN).
As of June 30, 2025, Galectin reported $13.8 million in cash and cash equivalents, along with a $10 million credit line, providing a funding runway through June 2026 without the need for immediate dilutive financing (Investor.GalectinTherapeutics).
The company remains unprofitable, posting a GAAP net loss of $7.6 million (–$0.12/share) in Q2 2025 and reporting no revenue to cover ongoing R&D and general and administrative costs (Investor.GalectinTherapeutics).
Heavy dependence on related-party financing—including $88 million in credit lines and convertible notes provided by its chairman—increases financial obligations and brings considerable dilution risk to shareholders (Panabee).
GALT shares dropped 37.41% intraday on June 20, 2025, reflecting ongoing skepticism among investors regarding its clinical and financial outlook, even after the release of new data (ATTN).
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2025.
GALT Financial Performance
Revenues and expenses
GALT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galectin Therapeutics stock?
Galectin Therapeutics (GALT) has a market cap of $302M as of October 12, 2025.
What is the P/E ratio for Galectin Therapeutics stock?
The price to earnings (P/E) ratio for Galectin Therapeutics (GALT) stock is 0 as of October 12, 2025.
Does Galectin Therapeutics stock pay dividends?
No, Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Galectin Therapeutics dividend payment date?
Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Galectin Therapeutics?
Galectin Therapeutics (GALT) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.